Abstract:Objective: The literature supporting the role of a specific drug in the onset of drug-induced antineutrophil cytoplasmic antibody-associated vasculitis (AAV) mainly relies on case reports or short series and implicates old treatments. The advent of new treatments may have modified the epidemiology of these adverse drug reactions. This study was undertaken to update the list of drugs associated with AAV by using a pharmacovigilance-based data mining approach. Methods: We collected data on adverse drug reactions reported using the Medical Dictionary for Regulatory Activities preferred term "anti-neutrophil cytoplasmic antibody positive vasculitis" up to November 2020 from the World Health Organization pharmacovigilance database (VigiBase). For each retrieved drug, a case-noncase analysis was performed, and disproportionate reporting was calculated by using the information component (IC). A positive IC025 value, which is the lower end of the 95% credibility interval, was considered significant. Results: A total of 483 deduplicated individual case safety reports of drug-induced AAV involving 15 drugs with an IC025 >0 were retrieved. Of the individuals with drug-induced AAV for whom data on sex were available (n = 371), 264 (71.2%) were women. The median age at onset of drug-induced AAV was 62 years (quartile 1 [Q1]-Q3 45-72 years), and the median time from the introduction of the suspected drug to the onset of drug-induced AAV was 9 months (Q1-Q3 1-36 months). Drug-induced AAV was considered serious in 472 (98.1%), and was fatal in 43 (8.9%), of 481 cases. The drugs associated with the highest disproportionate reporting were hydralazine, propylthiouracil, thiamazole, sofosbuvir, minocycline, carbimazole, mirabegron, and nintedanib. Conclusion: Our findings strengthen the evidence of an association of AAV with previously suspected drugs, but also identify 3 new drugs that may cause drug-induced AAV. Particular attention should be given to these drugs by prescribers and in experimental studies.

Drug-induced valvular heart disease: an update

Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists

Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment

A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies

Valvular Heart Disease: New Concepts in Pathophysiology and Therapeutic Approaches

Drug-induced AF: Arrhythmogenic Mechanisms and Management Strategies

Current and emerging drug targets in heart failure treatment

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

Drug interactions between non-steroidal anti-inflammatory drugs and cardiovascular treatments (except anti-agregant therapy).

Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

Drug-induced mitochondrial dysfunction and cardiotoxicity

Drug-Induced Myopathies: A Comprehensive Review and Update

Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review

Drug–drug interactions between clopidogrel and novel cardiovascular drugs

Pharmacotherapy in inherited and acquired ventricular arrhythmia in structurally normal adult hearts

Narrative Review of Heart Failure Related to Cocaine Consumption and Its Therapeutic Management

Review : Pharmacological Management of Atrial Fibrillation: An Update

Review Article: Drug-induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update